ShangPharma appoints chief biologics officer
This article was originally published in Scrip
Executive Summary
Contract research organization, ShangPharma has named Dr Mitchell Reff chief biologics officer, effective from 13 January 2014. Prior to joining the Shanghai, China-based firm Dr Reff held a number of positions at Biogen Idec during a 21-year career with the firm, including vice-president of discovery oncology. At ShangPharma he will join the ChemPartner's Biologics Division, which offers pharmaceutical and biotechnology companies strategic and technical expertise to discover and manufacture novel biologics.
You may also be interested in...
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.